All In Biotech

Drug Trial Radar · NCT07708285

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

A Multicenter, Open-Label Study of Luvometinib in Combination With Serplulimab for the Treatment of NF2-Related Tumors

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.

Conditions

  • NF2-related Schwannomatosis
  • NF2
  • Neurofibromatosis Type 2
  • Vestibular Schwannoma
  • Meningioma

Interventions

  • LuvometinibDrug

    Oral once daily per predetermined dosage per protocol.

  • SerplulimabDrug

    Intravenous infusion per predetermined dosage per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) or Hearing Response Rate (HRR)Time frame: 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.